摘要
目的:比较阿立哌唑和利培酮治疗女性精神分裂症患者的疗效及安全性。方法:女性精神分裂症患者60例,随机分为阿立哌唑组30例和利培酮组30例,疗程12周。采用阳性与阴性症状量表(PANSS)评价疗效,治疗中采用副作用量表(TESS)及实验室检查评价安全性。结果:阿立哌唑组显效率为75%,有效率为89.29%,利培酮组分别为73.08%和92.31%,两组结果无显著差异;阿立哌唑组体质量较治疗前无显著增加,利培酮组体质量增加明显,且出现多例闭经。结论:阿立哌唑治疗女性精神分裂症疗效与利培酮相当,且较为安全。
Objective： To evaluate the efficacy and safety of aripiprazole and risperidone in the treatment of female schizophrenics. Method： Sixty female schizophrenic patients were randomly divided into aripiprazole group （n=30） and risperidone group （n=30）. The therapeutic period was 12 weeks. Positive and negative symptoms scale （PANSS） and the treatment emergent symptoms scale （TESS） were used to evaluate the efficacy and the safety, respectively. Result： There were no significant differences between two groups in both markedly response rate （75% vs 73.08%） and improved rate （89.29% vs 92.31%）. The body weights in aripirazole group were not significantly increased after treatment, but they were in risperdone group and the menstruation was lost in part as well. Conclusion： Aripirazole is safer and has similar efficacy to risperidone in the treatment of female schizophrenic patients.
出处
《上海医药》
CAS
2012年第8期27-29,共3页
Shanghai Medical & Pharmaceutical Journal
